Detalhe da pesquisa
1.
Drugging an undruggable pocket on KRAS.
Proc Natl Acad Sci U S A
; 116(32): 15823-15829, 2019 08 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31332011
2.
Publisher Correction: BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design.
Nat Chem Biol
; 15(8): 846, 2019 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-31267096
3.
BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design.
Nat Chem Biol
; 15(7): 672-680, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31178587
4.
Fragment-based discovery of a chemical probe for the PWWP1 domain of NSD3.
Nat Chem Biol
; 15(8): 822-829, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31285596
5.
Sensitivity and engineered resistance of myeloid leukemia cells to BRD9 inhibition.
Nat Chem Biol
; 12(9): 672-9, 2016 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-27376689
6.
Reply to Tran et al.: Dimeric KRAS protein-protein interaction stabilizers.
Proc Natl Acad Sci U S A
; 117(7): 3365-3367, 2020 02 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-32047042
7.
Discovery of a Chemical Probe to Study Implications of BPTF Bromodomain Inhibition in Cellular and inâ vivo Experiments.
ChemMedChem
; 18(6): e202200686, 2023 03 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-36649575
8.
A selective and orally bioavailable VHL-recruiting PROTAC achieves SMARCA2 degradation in vivo.
Nat Commun
; 13(1): 5969, 2022 10 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36216795
9.
Fragment Optimization of Reversible Binding to the Switch II Pocket on KRAS Leads to a Potent, In Vivo Active KRASG12C Inhibitor.
J Med Chem
; 65(21): 14614-14629, 2022 11 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36300829
10.
Discovery of potent and selective HER2 inhibitors with efficacy against HER2 exon 20 insertion-driven tumors, which preserve wild-type EGFR signaling.
Nat Cancer
; 3(7): 821-836, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35883003
11.
Unconventional tethering of Ulp1 to the transport channel of the nuclear pore complex by karyopherins.
Nat Cell Biol
; 5(1): 21-7, 2003 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-12471376
12.
One Atom Makes All the Difference: Getting a Foot in the Door between SOS1 and KRAS.
J Med Chem
; 64(10): 6569-6580, 2021 05 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-33719426
13.
BI-3406, a Potent and Selective SOS1-KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK Inhibition.
Cancer Discov
; 11(1): 142-157, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32816843
14.
Selective and Potent CDK8/19 Inhibitors Enhance NK-Cell Activity and Promote Tumor Surveillance.
Mol Cancer Ther
; 19(4): 1018-1030, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32024684
15.
Start Selective and Rigidify: The Discovery Path toward a Next Generation of EGFR Tyrosine Kinase Inhibitors.
J Med Chem
; 62(22): 10272-10293, 2019 11 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-31689114
16.
Intracellular Trapping of the Selective Phosphoglycerate Dehydrogenase (PHGDH) Inhibitor BI-4924 Disrupts Serine Biosynthesis.
J Med Chem
; 62(17): 7976-7997, 2019 09 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31365252
17.
The novel BET bromodomain inhibitor BI 894999 represses super-enhancer-associated transcription and synergizes with CDK9 inhibition in AML.
Oncogene
; 37(20): 2687-2701, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29491412
18.
Chemically Induced Degradation of the Oncogenic Transcription Factor BCL6.
Cell Rep
; 20(12): 2860-2875, 2017 Sep 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-28930682
19.
Discovery of Novel Spiro[3H-indole-3,2'-pyrrolidin]-2(1H)-one Compounds as Chemically Stable and Orally Active Inhibitors of the MDM2-p53 Interaction.
J Med Chem
; 59(22): 10147-10162, 2016 11 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-27775892
20.
Structure-Based Design of an in Vivo Active Selective BRD9 Inhibitor.
J Med Chem
; 59(10): 4462-75, 2016 05 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-26914985